Roslin Innovation Centre opens its doors to gene control experts Synpromics Ltd

This move for Synpromics will facilitate the development and commercialisation of synthetic promoters for gene and cell therapy products and bioprocess applications.

Synthetic promoters are DNA sequences that do not exist in nature and are designed to regulate the activity of genes, controlling a gene's ability to produce its own uniquely encoded protein. Currently, within the biotech industry, naturally occurring promoters are used to drive protein production. Synpromics is the industry leader in gene control, developing custom-built synthetic promoters that can be used in a variety of applications, including cell and gene based medicine, biologics manufacturing and viral vector bioprocessing.

The company has grown rapidly over the past two years as it expanded its portfolio of international customers, including leading gene therapy companies and multi-national technology corporations, such as GE Healthcare.

“Roslin Innovation Centre offers genuine opportunities for leading innovation companies to be part of an integrated and collaborative community and we very much look forward to engaging further with Synpromics.”

“Synpromics is one of the UK’s most innovative companies working in gene medicine and is an ideal fit for our innovative tenant profile. Synpromics’ innovation has been attracting attention within the life sciences community and we look forward to providing an environment conducive for the business to realise its long-term growth ambition.”

John Mackenzie, CEO of Roslin Innovation Centre

“Synpromics’ technology has been validated through partnerships with some of the world’s leading gene medicine companies. The rapid expansion of the business required us to seek larger facilities and this corresponded with the opening of the new Roslin Innovation Centre.”

“We see this move as an exciting opportunity to continue our growth, in an innovative environment within a dynamic and collaborative biotech community in central Scotland.”

David Venables, CEO of Synpromics

Further information on Synpromics